Biotech News

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

Salarius Pharmaceuticals (SLRX)Salarius PharmaceuticalsCompany update

Highly differentiated AI-powered D-MAV discovery platform targeting drug discovery in the multi-billion-dollar antiviral markets Company to participate in Virtual Investor Closing Bell event to discuss path forward today at 4:00 PM ET. Access the event here CAMBRIDGE, Mass.

Related news

NRIXNurix Therapeutics2026-11-03 21:01 EST

Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

KURAKura Oncology2026-10-13 11:30 EST

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

FATEFate Therapeutics2026-10-12 11:00 EST

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

ERASErasca2026-11-16 13:01 EST

Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise

CHRSCoherus BioSciences, Inc.2026-10-28 20:05 EST

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

BMYBMYBristol-Myers Squibb Company2026-11-19 11:59 EST

Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026

FATEFate Therapeutics2026-11-10 12:00 EST

Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

KYMRKymera2026-10-28 20:01 EST

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

Salarius Pharmaceuticals

Salarius Pharmaceuticals is a biotechnology company focused on oncology and epigenetic or related cancer biology. Its story is built around seeking targeted cancer therapies for difficult tumors.

Recent company news

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States